Journal article
The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time
Nicole L Prokopishyn, Brent R Logan, Deidre M Kiefer, Jennifer A Sees, Pintip Chitphakdithai, Ibrahim A Ahmed, Paolo N Anderlini, Amer M Beitinjaneh, Christopher Bredeson, Jan Cerny, Saurabh Chhabra, Andrew Daly, Miguel Angel Diaz, Nosha Farhadfar, Haydar A Frangoul, Siddhartha Ganguly, Dennis A Gastineau, Usama Gergis, Gregory A Hale, Peiman Hematti Show all
Biology of Blood and Marrow Transplantation | ELSEVIER SCIENCE INC | Published : 2019
Abstract
Bone marrow (BM) is an essential source of hematopoietic stem cell grafts for many allogeneic hematopoietic cell transplant (HCT) recipients, including adult patients (for specific diseases and transplantation strategies) and the majority of pediatric recipient. However, since the advent of granulocyte colony-stimulating factor-mobilized peripheral blood stem cell (PBSC) grafts, there has been a significant decrease in the use of BM in HCT, thought to be due mainly to the increased logistical challenges in harvesting BM compared with PBSCs, as well as generally no significant survival advantage of BM over PBSCs. The decreased frequency of collection has the potential to impact the quality of..
View full abstractGrants
Awarded by Public Health Service
Awarded by National Institute of Allergy and Infectious Diseases
Awarded by NCI
Awarded by Health Resources and Services Administration
Awarded by NATIONAL CANCER INSTITUTE
Awarded by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Funding Acknowledgements
The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement 1U24HL138660 from the NHLBI and NCI; Contract HHSH250201700006C with the Health Resources and Services Administration; Grants N00014-17-1-2388, N00014-17-1-2850, and N00014-18-1-2045 from the Office of Naval Research; and grants from Adaptive Biotechnologies, *Amgen, anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Be The Match Foundation, *bluebird bio, *Bristol Myers Squibb Oncology, *Celgene, *Chimerix, *CytoSen Therapeutics, Fred Hutchinson Cancer Research Center; Gamida Cell, Gilead Sciences, HistoGenetics, Immucor, *Incyte, Janssen Scientific Affairs, *Jazz Pharmaceuticals, Karius, Karyopharm Therapeutics, *Kite Pharma, Medac, *Mediware, The Medical College of Wisconsin, *Merck & Co, *Mesoblast, MesoScale Diagnostics, Millennium, *Miltenyi Biotec, Mundipharma EDO, National Marrow Donor Program; Novartis Pharmaceuticals, PCORI, *Pfizer, *Pharmacyclics, PIRCHE, *Sanofi Genzyme, *Seattle Genetics, Shire, Spectrum Pharmaceuticals, St. Baldrick's Foundation, Swedish Orphan Biovitrum, *Takeda Oncology, and the University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US Government.